Press release: Uppsala,
The subscription period for the warrants of series TO1 2019 starts
Original terms for the warrants regarding subscription price and amount of shares
Each warrant, in accordance with the terms for the warrants of series TO1 2019, entitles the owner to subscribe for one (1) new share in the Company.
The subscription price for shares through the use of warrants corresponds to 70 percent of the volume weighted average price of the Company's share on
Terms after adjustment
The Company's
The result of the adjustment, and the judgement thereof, is that each warrant entitles the owner the right to subscribe to one point eighty-four (1.84) new shares in the Company. The number of shares will be rounded down to the closest whole number of shares. Hence the 7,790,823 outstanding warrants of series TO1 2019 will, at most, be used for the subscription of 14,335,114 shares.
The subscription price for shares through the use of warrants amounts to
The last trading day for the warrants of series 1 2019 is
Note that the warrants that are not used to subscribe for new shares, or are sold in the market before
How warrants are used:
Trustee registered warrants (Custody account)
Subscription and payment with the use of warrants shall be made in accordance with instructions from each trustee. Please contact your trustee for additional information.
Directly registered warrants (Securities account)
No accounts for issuing nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form. The warrants will then be replaced by interim shares (IS) awaiting registration at the Swedish Companies Registration Office.
The application form regarding payment will be available at Dicots website, www.dicot.se and on the issuing institution
For additional information, please contact:
Göran Beijer, CEO
Tel: +46 70-663 60 09
Email: goran.beijer@dicot.se
Dicot is a pharmaceutical company focused on drug discovery and the development of novel lifestyle drugs to enrich patients' lives. The Company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The Company's lead drug candidate, Libiguin®, for the treatment of sexual dysfunctions, is in a stage of pre-clinical development. Dicot is listed on the
https://news.cision.com/dicot-ab--publ-/r/the-subscription-price-for-the-exercise-of-warrants-of-series-to1-2019-in-dicot-ab-has-been-set-to-s,c3204643
https://mb.cision.com/Main/17172/3204643/1312191.pdf
(c) 2020 Cision. All rights reserved., source